Proceedings of the National Academy of Sciences · 2020 · 38 citations · 20 references
Life SciencesBiochemistryChemical BiologyDrug DiscoveryEnzyme MechanismEnzymologyEnzyme ActivationEnzyme ActivatorsEnzyme InhibitionEnzyme KineticsLigand BindingProtein-ligand InteractionsActivationEnzyme Inhibition KineticsEnzyme Inhibitor DiscoveryEnzyme-inhibitor BindingInhibitor SelectivityLigand-induced ActivationLigand-induced Enzyme ActivationTarget-ligand Interactions
Startling reports described the paradoxical triggering of the human mitogen-activated protein kinase pathway when a small-molecule inhibitor specifically inactivates the BRAF V600E protein kinase but not wt-BRAF. We performed a conceptual analysis of the general phenomenon "activation by inhibition" using bacterial and human HtrA proteases as models. Our data suggest a clear explanation that is based on the classic biochemical principles of allostery and cooperativity. Although substoichiometric occupancy of inhibitor binding sites results in partial inhibition, this effect is overrun by a concomitant activation of unliganded binding sites. Therefore, when an inhibitor of a cooperative enzyme does not reach saturating levels, a common scenario during drug administration, it may cause the contrary of the desired effect. The implications for drug development are discussed.
20
Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
Sonja J. Heidorn, Carla Milagre, Steven R. Whittaker et al. · Cell · 2010 · 1.5K citations · Full text
Crystal structure of DegP (HtrA) reveals a new protease-chaperone machine
T. Krojer, M. Garrido-Franco, Robert Huber et al. · Nature · 2002 · 408 citations